A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ The criteria are:
• Patients aged 18 years and above
• English (conversational level) speaking, with the ability to give informed consent
• Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Locations
United States
Texas
MD Anderson Cancer Center
RECRUITING
Houston
Contact Information
Primary
Y. Jeff Li, MD
yli61@mdanderson.org
713-409-1565
Time Frame
Start Date: 2024-09-11
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 20
Related Therapeutic Areas
Sponsors
Leads: M.D. Anderson Cancer Center